Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single Center, Open-Label, Single-Dose, Cross-over, Bioavailability Study of MGL-3196 Tablets Compared to Capsules in Healthy Subjects

Next Previous
Trial Profile

A Single Center, Open-Label, Single-Dose, Cross-over, Bioavailability Study of MGL-3196 Tablets Compared to Capsules in Healthy Subjects

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Feb 2018

At a glance

  • Drugs MGL-3196 (Primary)
  • Indications Hyperlipoproteinaemia type IIa; Non-alcoholic steatohepatitis
  • Focus Pharmacokinetics
  • Sponsors Madrigal Pharmaceuticals

    • Most Recent Events

    • 09 Feb 2018 Status changed from not yet recruiting to active, no longer recruiting.
    • 31 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top